Cargando…

Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with (213)Bi-substance P analogue

BACKGROUND: Glioblastoma multiforme (GBM), the most common malignant brain tumor, mainly manifests as a primary de novo and less frequently as a secondary glial neoplasm. GBM has been demonstrated to overexpress the NK-1 receptor and substance P can be used as a ligand for targeted therapy. Alpha em...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krolicki, Leszek, Bruchertseifer, Frank, Kunikowska, Jolanta, Koziara, Henryk, Królicki, Bartosz, Jakuciński, Maciej, Pawlak, Dariusz, Apostolidis, Christos, Mirzadeh, Saed, Rola, Rafał, Merlo, Adrian, Morgenstern, Alfred
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061489/ https://www.ncbi.nlm.nih.gov/pubmed/29713762 http://dx.doi.org/10.1007/s00259-018-4015-2

Ejemplares similares

Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma – safety and efficacy
por: Królicki, Leszek, et al.
Publicado: (2021)

Expression of glutamate carboxypeptidase II in the glial tumor recurrence evaluated in vivo using radionuclide imaging
por: Kunikowska, Jolanta, et al.
Publicado: (2022)

Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?
por: Krolicki, Leszek, et al.
Publicado: (2023)

An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
por: Morgenstern, Alfred, et al.
Publicado: (2018)

Targeted alpha therapy for glioblastoma
por: Kunikowska, Jolanta, et al.
Publicado: (2022)

Nuclear imaging and therapy in oncology in Poland in 2021–2022
por: Kunikowska, Jolanta, et al.
Publicado: (2023)

Tumor uptake in glioblastoma multiforme after IV injection of [(177)Lu]Lu-PSMA-617
por: Kunikowska, Jolanta, et al.
Publicado: (2020)

Prostate MRI – an update for the referring urologist
por: Czarniecki, Marcin, et al.
Publicado: (2016)

Clinical results of radionuclide therapy of neuroendocrine tumours with (90)Y-DOTATATE and tandem (90)Y/(177)Lu-DOTATATE: which is a better therapy option?
por: Kunikowska, Jolanta, et al.
Publicado: (2011)

Supply and Clinical Application of Actinium-225 and Bismuth-213
por: Morgenstern, Alfred, et al.
Publicado: (2020)

Ga-68-PSMA-11 PET/CT in Patients with Biochemical Recurrence of Prostate Cancer after Primary Treatment with Curative Intent—Impact of Delayed Imaging
por: Kunikowska, Jolanta, et al.
Publicado: (2022)

Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics
por: Šimeček, Jakub, et al.
Publicado: (2018)

The Safety and Efficacy of the Repeated PRRT with [(90)Y]Y/[(177)Lu]Lu-DOTATATE in Patients with NET
por: Zemczak, Anna, et al.
Publicado: (2021)

[(68) Ga]Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma
por: Kunikowska, Jolanta, et al.
Publicado: (2020)

First‐Generation Bispidine Chelators for (213)Bi(III) Radiopharmaceutical Applications
por: Bruchertseifer, Frank, et al.
Publicado: (2020)

Tandem peptide receptor radionuclide therapy using (90)Y/(177)Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience
por: Kunikowska, Jolanta, et al.
Publicado: (2020)

What parameters from (18)F-FDG PET/CT are useful in evaluation of adrenal lesions?
por: Kunikowska, Jolanta, et al.
Publicado: (2014)

Periaqueductal/periventricular gray deep brain stimulation for the treatment of neuropathic facial pain
por: Mandat, Victor, et al.
Publicado: (2023)

Radium and Francium beam tests to produce 225Ac/ 213Bi generators at CERN-MEDICIS
por: Bruchertseifer, Frank, et al.
Publicado: (2015)

Long-Term Toxicity of (213)Bi-Labelled BSA in Mice
por: Dorso, Laëtitia, et al.
Publicado: (2016)

(213)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
por: Kratochwil, C., et al.
Publicado: (2014)

Diverse metabolic response of cancer cells treated with a (213)Bi-anti-EGFR-immunoconjugate
por: Feuerecker, Benedikt, et al.
Publicado: (2021)

Radioimmunotherapy of micrometastases in lung with vascular targeted(213)Bi
por: Kennel, S J, et al.
Publicado: (1999)

In Vitro comparison of (213)Bi- and (177)Lu-radiation for peptide receptor radionuclide therapy
por: Chan, Ho Sze, et al.
Publicado: (2017)

Alpha-Particle Emitting (213)Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of Oxygenation
por: Wulbrand, Christian, et al.
Publicado: (2013)

“To be or not to be” for PET in rheumatology. A marriage of love or of convenience?
por: Królicki, Leszek
Publicado: (2017)

Cubosomal Lipid Formulation for Combination Cancer Treatment: Delivery of a Chemotherapeutic Agent and Complexed α-Particle Emitter (213)Bi
por: Cytryniak, Adrianna, et al.
Publicado: (2022)

Assessment of (213)Bi-anti-EGFR MAb treatment efficacy in malignant cancer cells with [1-(13)C]pyruvate and [(18)F]FDG
por: Feuerecker, Benedikt, et al.
Publicado: (2019)

The Assessment of Subregions in the Frontal Lobe May Be Feasible in the Differential Diagnosis of Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P) and Multiple System Atrophy (MSA)
por: Alster, Piotr, et al.
Publicado: (2022)

The Use of Cerebellar Hypoperfusion Assessment in the Differential Diagnosis of Multiple System Atrophy with Parkinsonism and Progressive Supranuclear Palsy-Parkinsonism Predominant
por: Madetko-Alster, Natalia, et al.
Publicado: (2022)

Optimizing labelling conditions of (213)Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy
por: Chan, Ho Sze, et al.
Publicado: (2016)

Therapeutic Performance Evaluation of (213)Bi-Labelled Aminopeptidase N (APN/CD13)-Affine NGR-Motif ([(213)Bi]Bi-DOTAGA-cKNGRE) in Experimental Tumour Model: A Treasured Tailor for Oncology
por: Képes, Zita, et al.
Publicado: (2023)

Influence of tumour size on the efficacy of targeted alpha therapy with (213)Bi-[DOTA(0),Tyr(3)]-octreotate
por: Chan, Ho Sze, et al.
Publicado: (2016)

PEM or MBI?
por: Zdanowski, Paweł, et al.
Publicado: (2016)

Is MRPI 2.0 More Useful than MRPI and M/P Ratio in Differential Diagnosis of PSP-P with Other Atypical Parkinsonisms?
por: Madetko, Natalia, et al.
Publicado: (2022)

Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the (213)Bi-labeled monoclonal antibody MX35 in an ovarian cancer model
por: Gustafsson-Lutz, Anna, et al.
Publicado: (2017)

The Rate of Decrease in Brain Perfusion in Progressive Supranuclear Palsy and Corticobasal Syndrome May Be Impacted by Glycemic Variability—A Pilot Study
por: Alster, Piotr, et al.
Publicado: (2021)

Level structure in $^{213}Bi$
por: Chumin, V G, et al.
Publicado: (1996)

Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis
por: Derrien, Aurélie, et al.
Publicado: (2015)

The role of ultrasound and nuclear medicine methods in the preoperative diagnostics of primary hyperparathyroidism
por: Nieciecki, Michał, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q9pk6f0udtb20n7hg9ju6vhb85